文献速递前列腺癌

达罗他胺联合ADT和多西他赛在转移性激素敏感性前列腺癌中的年龄相关疗效与安全性:ARASENS 3期试验亚组分析

Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.
PubMed 文献 · Eur Urol Oncol · 2025-11-04

ARASENS 3期试验的年龄亚组分析显示,在转移性激素敏感性前列腺癌患者中,无论年龄<75岁(n=1086)或≥75岁(n=219),达罗他胺联合雄激素剥夺治疗(ADT)和多西他赛较安慰剂均改善总生存期、延迟至转移性去势抵抗性前列腺癌的时间及至后续治疗启动时间,且安全性相似;两组多数患者有合并症(<75岁94%,≥75岁97%)。

要点

  • 年龄≥75岁患者(n=219)接受达罗他胺联合ADT和多西他赛较安慰剂改善总生存(HR 0.61,95%CI 0.41-0.91)。
  • 年龄<75岁患者(n=1086)同样获益(HR 0.70,95%CI 0.58-0.84),两组安全性相似但老年患者不良事件发生率略高。
  • 无论年龄,达罗他胺联合ADT和多西他赛可作为转移性激素敏感性前列腺癌的标准三联治疗。

核心结论

  • 在ARASENS试验的219例年龄≥75岁患者中,达罗他胺较安慰剂改善疗效且安全性良好,与<75岁患者一致。
  • 达罗他胺联合ADT和多西他赛可作为转移性激素敏感性前列腺癌的标准三联治疗,不受年龄限制。

研究设计与样本

  • ARASENS 3期试验的事后亚组分析,比较年龄<75岁(n=1086)和≥75岁(n=219)患者的结局。
  • 患者接受达罗他胺600 mg或安慰剂口服每日两次,联合ADT和多西他赛。

主要发现

  • 总生存:<75岁HR 0.70(95%CI 0.58-0.84),≥75岁HR 0.61(95%CI 0.41-0.91)。
  • 至转移性去势抵抗性前列腺癌时间:<75岁HR 0.35(95%CI 0.30-0.43),≥75岁HR 0.42(95%CI 0.28-0.64)。
  • 至后续治疗启动时间:<75岁HR 0.40(95%CI 0.34-0.48),≥75岁HR 0.35(95%CI 0.22-0.54)。
  • 两组治疗中出现的不良事件相似,老年患者发生率略高。
  • 两组多数患者有合并症(<75岁94%,≥75岁97%)和合并用药(中位数8-9种)。

临床怎么用

  • 对于转移性激素敏感性前列腺癌患者,无论年龄,可考虑达罗他胺联合ADT和多西他赛作为标准三联治疗。
  • 老年患者(≥75岁)使用该方案时需关注合并症和合并用药,但疗效和安全性仍支持使用。

局限性

  • 该分析为事后亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate cancer is typically a disease of older men. As patients age, they develop comorbidities and require more medications, which may adversely affect or be affected by prostate cancer treatments. We investigated whether the survival benefits and favorable safety profile of darolutamide in the phase 3 ARASENS trial could be seen regardless of age. METHODS: Patients received darolutamide 600 mg or placebo orally twice daily plus androgen-deprivation therapy and docetaxel. Outcomes were assessed in subgroups of patients aged <75 yr (n = 1086) and ≥75 yr (n = 219). KEY FINDINGS AND LIMITATIONS: Most patients in both age groups had comorbidities (<75 yr: 94%; ≥75 yr: 97%) and concomitant medications (median 8-9). In both age subgroups, compared with placebo, darolutamide increased overall survival (<75 yr: hazard ratio 0.70 [95% confidence interval 0.58-0.84]; ≥75 yr: 0.61 [0.41-0.91]), delayed time to metastatic castration-resistant prostate cancer (<75 yr: 0.35 [0.30-0.43]; ≥75 yr: 0.42 [0.28-0.64]), and delayed time to initiation of subsequent therapy (<75 yr: 0.40 [0.34-0.48]; ≥75 yr: 0.35 [0.22-0.54]). Treatment-emergent adverse events were similar in the darolutamide/placebo groups, with slightly higher incidences in older patients. This analysis is limited by its post hoc nature. CONCLUSIONS AND CLINICAL IMPLICATIONS: In the 219 patients aged ≥75 yr in ARASENS, darolutamide demonstrated improved efficacy versus placebo and favorable safety, consistent with the findings in patients aged <75 yr. Thus, darolutamide and androgen-deprivation therapy with docetaxel can be considered a standard of care triplet therapy for metastatic hormone-sensitive prostate cancer regardless of patients' age.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Carles J, Tombal B, Hussain M, et al. Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial. Eur Urol Oncol. 2025. PMID: 41193271. doi:10.1016/j.euo.2025.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。